Phase 1 Pancreatic Ductal Adenocarcinoma trials recruiting now

All Pancreatic Ductal Adenocarcinoma trials, every phase

Other phases for Pancreatic Ductal Adenocarcinoma

Phase 1 Pancreatic Ductal Adenocarcinoma trials

• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
  NCT06428409 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
  NCT07629960 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
  NCT07024615 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of GV20-0251 in Advanced or Refractory Solid Tumors
  NCT07106827 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
  NCT06131840 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 48 locations
• A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
  NCT06598007 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
  NCT07094204 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• AB122 Platform Study
  NCT04999761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Lead-212 PSV359 Therapy for Patients With Solid Tumors
  NCT06710756 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 22 locations
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
  NCT04146298 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
  NCT06673017 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
  NCT06218914 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
  NCT07261631 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 16 locations
• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
  NCT06562192 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 29 locations
• SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
  NCT04150042 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
  NCT05799274 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
  NCT05482893 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
  NCT06005493 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
  NCT06128551 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 55 locations
• Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
  NCT07589205 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
  NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
  NCT06084481 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
  NCT05257993 · Phase: Phase 1, Phase 2 · Ages: 19 Years to 79 Years · Sex: All (male and female) · 4 locations
• TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
  NCT07284277 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  NCT04851119 · Phase: Phase 1, Phase 2 · Ages: 12 Months to 30 Years · Sex: All (male and female) · 42 locations
• [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
  NCT07432633 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
  NCT03608631 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.